Silencing of GATA3 defines a novel stem cell-like subgroup of ETP-ALL.

Lars FranseckyM NeumannS HeeschC SchleeJ Ortiz-TanchezS HellerM MossnerS SchwartzL H MochmannK IsaakidisL BastianU R KeesT HeroldK SpiekermannN GökbugetC D Baldus

Published in: Journal of hematology & oncology (2016)

We propose GATA3low ETP-ALL as a novel stem cell-like leukemia with implications for the use of myeloid-derived therapies.

Keyphrases

stem cells
transcription factor
bone marrow
acute myeloid leukemia
dendritic cells
cell therapy
mesenchymal stem cells
clinical trial
immune response
phase iii
study protocol
double blind
placebo controlled